TY - JOUR AU - Shariat, S. F. AU - Kattan, M. W. AU - Vickers, A. J. AU - Karakiewicz, P. I. AU - Scardino, P. T. PY - 2009 DA - 2009// TI - Critical review of prostate Cancer predictive tools JO - Future Oncol VL - 5 UR - https://doi.org/10.2217/fon.09.121 DO - 10.2217/fon.09.121 ID - Shariat2009 ER - TY - JOUR AU - Lee, D. J. AU - Cha, E. K. AU - Dubin, J. M. PY - 2012 DA - 2012// TI - Novel therapeutics for the Management of Castration-Resistant Prostate Cancer (CRPC) JO - BJU Int VL - 109 UR - https://doi.org/10.1111/j.1464-410X.2011.10643 DO - 10.1111/j.1464-410X.2011.10643 ID - Lee2012 ER - TY - JOUR AU - Harzstak, A. L. AU - Small, E. J. PY - 2010 DA - 2010// TI - Castrate-resistant prostate Cancer: therapeutic strategies JO - Expert Opin Pharmacother VL - 11 UR - https://doi.org/10.1517/14656561003677382 DO - 10.1517/14656561003677382 ID - Harzstak2010 ER - TY - JOUR AU - Karantanos, T. AU - Corn, P. G. AU - Thompson, T. C. PY - 2013 DA - 2013// TI - Prostate Cancer progression after androgen deprivation therapy: mechanisms of castrate-resistance and novel therapeutic approaches JO - Oncogene VL - 32 UR - https://doi.org/10.1038/onc.2013.206 DO - 10.1038/onc.2013.206 ID - Karantanos2013 ER - TY - JOUR AU - Titus, M. A. AU - Schell, M. J. AU - Lih, F. B. AU - Tomer, K. B. AU - Mohler, J. L. PY - 2005 DA - 2005// TI - Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-05-0525 DO - 10.1158/1078-0432.CCR-05-0525 ID - Titus2005 ER - TY - JOUR AU - Zarour, L. AU - Alumkai, J. PY - 2010 DA - 2010// TI - Emerging therapies in castrate-resistant prostate Cancer JO - Curr Urol Rep VL - 11 UR - https://doi.org/10.1007/s11934-010-0104-x DO - 10.1007/s11934-010-0104-x ID - Zarour2010 ER - TY - JOUR AU - Scher, H. I. AU - Steineck, G. AU - Kelly, W. K. PY - 1995 DA - 1995// TI - Hormone-refractory (D3) prostate cancer: refining the concept JO - Urology VL - 46 UR - https://doi.org/10.1016/S0090-4295(99)80182-4 DO - 10.1016/S0090-4295(99)80182-4 ID - Scher1995 ER - TY - JOUR AU - Tilki, D. AU - Schaeffer, M. E. AU - Evans, C. P. PY - 2016 DA - 2016// TI - Understanding mechanism of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor JO - Eur Urol Focus VL - 2 UR - https://doi.org/10.1016/j.euf.2016.11.013 DO - 10.1016/j.euf.2016.11.013 ID - Tilki2016 ER - TY - JOUR AU - Yuan, X. AU - Cai, C. AU - Chen, S. AU - Chen, S. AU - Yu, Z. AU - Balk, S. P. PY - 2013 DA - 2013// TI - Androgen receptor functions in castration-resistant prostate Cancer and mechanisms of resistance to new agents targeting the androgen Axis JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2013.235 DO - 10.1038/onc.2013.235 ID - Yuan2013 ER - TY - JOUR AU - Chandrasekar, T. AU - Yang, J. C. AU - Gao, A. C. AU - Evans, C. P. PY - 2015 DA - 2015// TI - Mechanism of resistance in castration-resistant prostate Cancer (CRPC) JO - Transl Androl Urol VL - 4 ID - Chandrasekar2015 ER - TY - JOUR AU - Mostagher, E. A. PY - 2013 DA - 2013// TI - Steroid hormone synthetic pathways in prostate Cancer JO - Transl Androl Urol VL - 2 UR - https://doi.org/10.3978/j.issn.2223-4683.2013.09.16 DO - 10.3978/j.issn.2223-4683.2013.09.16 ID - Mostagher2013 ER - TY - JOUR AU - Armandari, I. AU - Hamid, A. R. AU - Verhaegh, G. AU - Schalken, J. PY - 2014 DA - 2014// TI - Intratumoral Steroidogenesis in castration-resistant prostate Cancer: a target for therapy JO - Prostate Int VL - 2 UR - https://doi.org/10.12954/PI.14063 DO - 10.12954/PI.14063 ID - Armandari2014 ER - TY - JOUR AU - Lonergen, P. E. AU - Tindall, D. J. PY - 2011 DA - 2011// TI - Androgen receptor signaling in prostate Cancer development and progression JO - J Carcinog VL - 10 UR - https://doi.org/10.4103/1477-3163.83937 DO - 10.4103/1477-3163.83937 ID - Lonergen2011 ER - TY - JOUR AU - Li, J. AU - Ding, Z. AU - Wang, Z. PY - 2011 DA - 2011// TI - Androgen regulation of 5α-Reductase Isoenzymes in prostate Cancer: implications for prostate Cancer prevention JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0028840 DO - 10.1371/journal.pone.0028840 ID - Li2011 ER - TY - STD TI - Sigma Aldrich. Product. Life science: Antibodies. [Available from: https://www.sigmaaldrich.com/life-science/cell-biology/antibodies.html]. UR - https://www.sigmaaldrich.com/life-science/cell-biology/antibodies.html ID - ref15 ER - TY - JOUR AU - Vander Griend, D. J. AU - Litvinov, I. V. AU - Isaacs, J. T. PY - 2014 DA - 2014// TI - Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation JO - Int J Biol Sci VL - 10 UR - https://doi.org/10.7150/ijbs.8756 DO - 10.7150/ijbs.8756 ID - Vander Griend2014 ER - TY - JOUR AU - Lam, H. M. AU - Ouyang, B. AU - Chen, J. AU - Ying, J. AU - Wang, J. AU - Wu, C. L. PY - 2014 DA - 2014// TI - Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer JO - Endocr Relat Cancer VL - 21 UR - https://doi.org/10.1530/ERC-14-0402 DO - 10.1530/ERC-14-0402 ID - Lam2014 ER - TY - JOUR AU - Liu, C. AU - Lou, W. AU - Zhu, Y. AU - Yang, J. C. AU - Nadiminty, N. AU - Gaikwad, N. W. PY - 2015 DA - 2015// TI - Intracrine androgens and AKR1C3 activation confer resistance to Enzalutamide in prostate Cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3080 DO - 10.1158/0008-5472.CAN-14-3080 ID - Liu2015 ER - TY - JOUR AU - He, M. AU - Liu, H. AU - Cao, J. PY - 2017 DA - 2017// TI - Predicting Castration-resistant prostate cancer after combined androgen blockade JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.22246 DO - 10.18632/oncotarget.22246 ID - He2017 ER - TY - STD TI - Cornford P, Bellmunt J, Colla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71(4):630–42. ID - ref20 ER - TY - JOUR AU - Chen, C. D. AU - Welsbie, D. S. AU - Tran, C. PY - 2004 DA - 2004// TI - Molecular determinants of resistance to antiandrogen therapy JO - Nat Med VL - 10 UR - https://doi.org/10.1038/nm972 DO - 10.1038/nm972 ID - Chen2004 ER - TY - JOUR AU - Koivisto, P. AU - Kononen, J. AU - Palmberg, C. PY - 1997 DA - 1997// TI - Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer JO - Cancer Res VL - 57 ID - Koivisto1997 ER - TY - JOUR AU - Visakorpi, T. AU - Hyytinen, E. AU - Koivisto, P. PY - 1995 DA - 1995// TI - In vivo amplification of the androgen receptor gene and progression of human prostate cancer JO - Nat Genet VL - 9 UR - https://doi.org/10.1038/ng0495-401 DO - 10.1038/ng0495-401 ID - Visakorpi1995 ER - TY - JOUR AU - Shibata, Y. AU - Suzuki, K. AU - Arai, S. PY - 2013 DA - 2013// TI - Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy JO - Andrology VL - 1 UR - https://doi.org/10.1111/j.2047-2927.2013.00068.x DO - 10.1111/j.2047-2927.2013.00068.x ID - Shibata2013 ER - TY - JOUR AU - Godoy, A. AU - Kawinski, E. AU - Li, Y. PY - 2011 DA - 2011// TI - 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression JO - Prostate VL - 71 UR - https://doi.org/10.1002/pros.21318 DO - 10.1002/pros.21318 ID - Godoy2011 ER - TY - JOUR AU - Luo, J. AU - Dunn, T. A. AU - Ewing, C. M. PY - 2003 DA - 2003// TI - Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma JO - Prostate VL - 57 UR - https://doi.org/10.1002/pros.10284 DO - 10.1002/pros.10284 ID - Luo2003 ER - TY - STD TI - Hamid AR, Pfeiffer MJ, et al. AKR1C3 is a biomarker and therapeutic target for Castration Resistant Prostate Cancer. Mol Med. 2013;18:1449–55. ID - ref27 ER - TY - JOUR AU - Alsinnawi, M. AU - Zhang, A. AU - Bianchi-Frias, D. AU - Burns, J. AU - Cho, E. AU - Zhang, X. PY - 2019 DA - 2019// TI - Association of prostate cancer SLCO gene expression with Gleason grade and alteration following androgen deprivation therapy JO - Prostate Cancer Prostatic Dis VL - 22 UR - https://doi.org/10.1038/s41391-019-0141-6 DO - 10.1038/s41391-019-0141-6 ID - Alsinnawi2019 ER - TY - JOUR AU - Terakawa, T. AU - Kastsuta, E. AU - Yan, L. AU - Turaga, N. AU - McDonald, K. A. AU - Fujisawa, M. PY - 2018 DA - 2018// TI - High expression of SLCO2B1 is asociated with prostate cancer recurrence after radical prostatectomy JO - Oncotarget VL - 9 UR - https://doi.org/10.18632/oncotarget.24453 DO - 10.18632/oncotarget.24453 ID - Terakawa2018 ER - TY - JOUR AU - Tiwari, R. AU - Manzar, N. AU - Bhatia, V. AU - Yadav, A. AU - Nengroo, M. A. AU - Datta, D. PY - 2020 DA - 2020// TI - Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-019-14184-0 DO - 10.1038/s41467-019-14184-0 ID - Tiwari2020 ER - TY - JOUR AU - Cheung, A. S. AU - Rooy, C. AU - Lebinger, I. AU - Rana, K. AU - Clarke, M. V. AU - How, J. M. PY - 2017 DA - 2017// TI - Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer JO - J Steroid Biochem Mol Biol VL - 174 UR - https://doi.org/10.1016/j.jsbmb.2017.07.029 DO - 10.1016/j.jsbmb.2017.07.029 ID - Cheung2017 ER -